No Data
No Data
DAH Sing Bank estimates that the second quarter performance of the medical technology company, DahMoo, was weak and adjusts the target price of its shares.
Morgan Stanley's report points out that under the continuous negative factors of anti-corruption in the mainland, it is believed that the market has anticipated the weak performance of medical technology companies in the second quarter. Investors are concerned about the timing and scale of the upcoming fiscal stimulus plan from the central government to set expectations for the medical technology stocks in the second half of this year and next year. At the same time, macro and policy factors may continue to drag down the growth of consumer and medical beauty companies. Among the medical technology companies covered by the Bank, it is expected that Time Medical Angel (06699.HK) will achieve a year-on-year increase of 11% in domestic sales in the first half of the year, with a drop in product average price of 3%, and overseas revenue exceeding RMB 0.15 billion. Microport.
China's Medical Device Market Value Hits $179B, 90th CMEF in Shenzhen to Feature a Plethora of Technological Products
Sinolink Securities: The pharmaceutical sector is expected to see an improvement in market conditions in the third quarter, and overall growth expectations for the second half of the year are optimistic.
Sinolink Securities released a research report stating that considering the improvement in the medical insurance settlement cycle, the expectation of policy improvement, and the recovery performance of the industry, as well as the fact that institutional medicine hold positions are at a low level, the medical sector will usher in an improved market situation in Q3.
Express News | China Securities Co.,Ltd.: We recommend keeping confidence in the pharmaceutical industry in the second half of the year, waiting for the right time.
Hong Kong's pharmaceutical stocks rebounded today! After a deep adjustment from the beginning of the year until now, can they achieve a bottom-up rebound?
Since 2024, innovative drugs have received a variety of benefits from the policy combination. From multi-dimensional support for speeding up the registration and evaluation of innovative drugs, promoting multi-tiered innovation, and reasonable pricing of new drugs, the policy has moved from 'encouraging large-scale innovation' to 'encouraging high-quality innovation'.
Chief Operations Officer of Sinocare Medical (06669.HK) was appointed as non-executive director.
First Trillium Medical -B (06669.HK) announced that Silvio Rudolf SCHAFFNER resigned as executive director and chief operating officer of the company today (12th), and was appointed as a non-executive director of the company due to his wish to devote more time to his personal affairs. (js / u) ~
No Data